Immune Dysfunction, Minimal Residual Disease and Patient Outcome in Nonmetastatic Cancer: Could Modulation of Immune Function Improve Outcome?

References

• HoshinoA, Costa-SilvaB, ShenTLet al.Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).
   PubMed Web of Science ®Google Scholar
• WieckowskiEU, VisusC, SzajnikM, SzczepanskiMJ, StorkusWJ, WhitesideTL. Tumor derived microvesicles promote regulatory T cell expansión and induce apoptosis in tumor reactive activated CD8+ lymphocytes. J. Immunol. 183, 3720–3730 (2009).
   PubMed Web of Science ®Google Scholar
• WhitesideTL. Immune modulation of T-cell and NK cell activities by tumour derived exosomes. Biochem. Soc. Trans. 41, 245–251 (2013).
   PubMed Web of Science ®Google Scholar
• SakaguchiS, MiyaraM, CostantinoCM, HaflerDA. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490–500 (2010).
   PubMed Web of Science ®Google Scholar
• WeiS, KryczekI, ZouW. Regulatory T-cell compartmentalization and trafficking. Blood 108, 426–431 (2006).
   PubMed Web of Science ®Google Scholar
• GeY, BohmHH, RathinasamyAet al.Tumor specific regulatory T cells from the bone marrow orchestrate antitumor immunity in breast cancer. Cancer Immunol. Res. 7, 1998–2012 (2019).
   PubMed Web of Science ®Google Scholar
• WolfAM, WolfD, SteuerM, GastlG, GunsiliusE, Gribeck-LoebensteinB. Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606–612 (2003).
   PubMed Web of Science ®Google Scholar
• BeyerM, SchultzeJL. Regulatory T cells in cancer. Blood 108, 804–811 (2006).
   PubMed Web of Science ®Google Scholar
• PetersenRP, CampaMJ, SperlazzaJet al.Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathological stage I NSCLC patients. Cancer 107, 2866–2872 (2006).
   PubMed Web of Science ®Google Scholar
• XueD, XiaT, WangJ, ChingM, WangS, ZhangC. Role of regulatory T cells and CD8+ lymphocytes in the dissemination of circulating tumour cells in primary invasive breast cancer. Oncol. Lett. 16, 3045–3053 (2018).
   PubMed Web of Science ®Google Scholar
• OhE, HongJW, YunCO. Regulatory T cells induce metastasis by activating Tgf-B and enhancing the epithelial-mesenchymal transition. Cells 8, 1837 (2019).
   Web of Science ®Google Scholar
• LiY, LiD, YangW, FuH, LiuY, LiY. Overexpression of the transcription factor FOXP3 in lung adenocarcinoma sustains malignant character by promoting G1/S transition gene CCND1. Tumour Biol. 37, 7395–7404 (2016).
   PubMedGoogle Scholar
• MegoM, GaoH, CohenENet al.Circulating tumor cells (CTC) are associated with defects in adaptive immunity in patients with inflammatory breast cancer. J. Cancer 7, 1095–1104 (2016).
   PubMed Web of Science ®Google Scholar
• BatesGJ, FoxSB, HanCet al.Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24, 5373–5380 (2006).
   PubMed Web of Science ®Google Scholar
• LiangY, ZhangF, LiHet al.Circulating tumor cells were associated with the number of T lymphocyte subsets and NK cells in peripheral blood in advanced non small cell lung cancer. Dis. Markers 2017, 5727815 (2017).
   PubMed Web of Science ®Google Scholar
• CampbellMJ, ScottJ, MaeckerHT, ParkJW, EssermanLJ. Immune dysfunction and micrometastasis in women with breast cancer. Breast Cancer Res. Treat. 91, 163–171 (2005).
   PubMed Web of Science ®Google Scholar
• MansiJ, MordenJ, BlissJM, NevilleM, CoombesRC. Bone marrow micrometastasis in early breast cancer – 30 year outcome. Br. J. Cancer 114, 243–247 (2016).
   PubMed Web of Science ®Google Scholar
• PantelK, Alix-PanabieresC. Bone marrow as a reservoir for disseminated tumour cells: a special source for liquid biopsy in cancer patients. Bonekey Rep. 3, 584 (2014).
   PubMedGoogle Scholar
• PantelK, BrakenhoffRH. Dissecting the metastatic cascade. Nat. Rev. Cancer 4, 448–456 (2004).
   PubMed Web of Science ®Google Scholar
• TengMW, SwannJB, KoebelCM, SchrieberRD, SmythMJ. Immune mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84, 988–993 (2008).
   PubMed Web of Science ®Google Scholar
• SaiB, XiangJ. Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy. J. Cell Mol. Med. 22, 5776–5786 (2018).
   PubMed Web of Science ®Google Scholar
• SelllittoA, GaliziaG, DeFanis Uet al.Behaviour of circulating CD4+ CD25+ Foxp3+ regulatory T cells in colon cancer patients undergoing surgery. J. Clin. Immunol. 31, 1095–1104 (2011).
   PubMed Web of Science ®Google Scholar
• ChenC, ChenD, ZhangYet al.Changes of CD4+ CD25+ FOXP3+ and CD8+CD28- regulatory T cells in non small cell lung cancer patients undergoing surgery. Int. Immunopharmacol. 18, 255–261 (2014).
   PubMed Web of Science ®Google Scholar
• NapoletanoC, BellatiF, LandiRet al.Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J. Cell. Mol. Med. 14, 2748–2759 (2010).
   PubMed Web of Science ®Google Scholar
• BraunS, KentenichC, JanniWet al.Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J. Clin. Oncol. 18, 80–86 (2000).
   PubMed Web of Science ®Google Scholar
• MurrayNP, AedoS, VillalonRet al.Effect of FOLFOX on minimal residual disease in stage III colon cancer and risk of relapse. Ecancermedicalscience 13, 935 (2019).
   PubMed Web of Science ®Google Scholar
• MurrayNP, AedoS, FuentealbaCet al.Minimal residual disease defines the risk andtime to biochemical failure in patients with pT2 and pT3a prostatecancer treated with radical prostatectomy: an observational prospective study. Urol. J. 17(3), 262–270 (2020).
   PubMed Web of Science ®Google Scholar
• MullerV, StahmannN, RiethdorfSet al.Circulating tumor cells in breast cancer: correlation to bone marrow metastasis, heterogenous response to systemic therapy and low proliferative activity. Clin. Cancer Res. 11, 3678–3685 (2005).
   PubMed Web of Science ®Google Scholar
• ScurrM, PembrokeT, BloomAet al.Low-dose cyclophosphamide induces antitumour T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 23, 6771–6780 (2017).
   PubMed Web of Science ®Google Scholar
• TonguM, HarashimaN, MonmaHet al.Metronomic chemotherapy with low dose cyclophosphamide plus gemcitabine can induce anti tumour T-cell immunity in vivo. Cancer Immunol. Immunother. 62, 383–391 (2012).
   PubMed Web of Science ®Google Scholar
• ChanOT, YangLX. The immunological effects of taxanes. Cancer Immunol. Imunother. 49, 181–185 (2000).
   PubMed Web of Science ®Google Scholar
• KrajnakS, SchnatzC, AlmstedtKet al.Low dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer – results of an exploratory case–control study. Breast Cancer Res. Treat. 182, 389–399 (2020).
   PubMed Web of Science ®Google Scholar
• MarzbaniE, InatsukaC, LuH, DisisML. The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev. Res. (Phil.) 6, 764–773 (2013).
   PubMed Web of Science ®Google Scholar
• BozionelloeV, MavroudisD, PerrakiMet al.Trastuzumab administration can effectively target chemotherapy resistant cytokeratin 19 mRNA positive tumour cells in peripheral blood and bone marrow of patients with breast cancer. Clin. Cancer Res. 10, 8185–8194 (2004).
   PubMed Web of Science ®Google Scholar
• KirchnerEM, RGerhards R, VoightmannR. Sequential immunochemotherapy and edrecolomab in the adjuvant therapy of breast cancer: reduction of 17-1A positive disseminated tumour cells. Ann. Oncol. 13, 1044–1048 (2002).
   PubMed Web of Science ®Google Scholar
• DisisML, StantonSE. Can immunity to breast cancer eliminate residual micrometastasis. Clin. Cancer Res. 19(23), 6398–6403 (2013).
   PubMed Web of Science ®Google Scholar
• WangHF, WangSS, HuangMC, LiangXH, TangYJ, TangYL. Targeting immune-mediated dormancy: a promising treatment of cancer. Front. Oncol. 9, 498 (2019).
   PubMed Web of Science ®Google Scholar